<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03720977</url>
  </required_header>
  <id_info>
    <org_study_id>diagnostic value of cd71</org_study_id>
    <nct_id>NCT03720977</nct_id>
  </id_info>
  <brief_title>Diagnostic Value and Biological Significant of cd71 in Lymphoid Disorders</brief_title>
  <official_title>Diagnostic Value and Biological Significant of cd71 in Lymphoid Dis Order</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marwa Aboelim Shafeik</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CD71 is expressed on activated B and T cells, macrophages, reticulocytes, erythroid
      precursors, and malignant tissues. , reflecting the requirement for iron in hemoglobin. ,
      CD71 expression is upregulated on immature proliferating cells and low levels on resting
      mature lymphocytes. In addition to this general function, CD71 appears to play a
      costimulatory role in T cell activation and receptor for IgA1 antibodies So it is growth
      receptor that may help in diagnosis of lymphoid disorder and in differentiation of malignant
      and benign that will be studied investigate CD71 expression in lymphoid disorders and its
      diagnostic value ,we from collect data patient and do rotune examination
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Routine investigations for diagnosis:

             -  CBC.

             -  Bone marrow aspiration morphology.

             -  Cytochemistry.

             -  Flow cytometry immunophenotyping.

             -  Bone marrow biopsy when indicated.

        2. Special investigation is flow cytometry examination of CD71 expression.

      sample size calculation ; sample size cases 39 sample size controls 39 total sample size 79
      sample will be collected from patient in hospital university ,Data will be analysed by SPSS
      program
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>determin diagnostic value of cd71 in lymphoid disorder</measure>
    <time_frame>baseline</time_frame>
    <description>Routine investigations for diagnosis:
CBC. Bone marrow aspiration morphology. Cytochemistry. Flow cytometry immunophenotyping. Bone marrow biopsy when indicated. Special investigation is flow cytometry examination of CD71 expression.
total sample size 79 person .sample will be collected from patient in hospital university ,Data will be analysed by SPSS program it is growth receptor is expressed on activated B and T cells, macrophages, reticulocytes, erythroid precursors, and malignant tissues</description>
  </primary_outcome>
  <enrollment type="Anticipated">139</enrollment>
  <condition>Lyphoid Disorders</condition>
  <condition>cd71</condition>
  <eligibility>
    <study_pop>
      <textblock>
        confidence level 95 sample size 139
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all patients wiil be diagnosed lymphoid disorders

        Exclusion Criteria:

          -  not present
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maged Salah, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University .clinical pathologydepartment</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marwa Aboelim</last_name>
    <phone>01012636292</phone>
    <email>marwaaboelim@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tagreed kamal, dr</last_name>
    <phone>01002286687</phone>
  </overall_contact_backup>
  <reference>
    <citation>Zhang Q, Steensma DP, Yang J, Dong T, Wu MX. Uncoupling of CD71 shedding with mitochondrial clearance in reticulocytes in a subset of myelodysplastic syndromes. Leukemia. 2019 Jan;33(1):217-229. doi: 10.1038/s41375-018-0204-z. Epub 2018 Jul 26.</citation>
    <PMID>30050123</PMID>
  </reference>
  <reference>
    <citation>Salzberger W, Martrus G, Bachmann K, Goebels H, He√ü L, Koch M, Langeneckert A, Lunemann S, Oldhafer KJ, Pfeifer C, Poch T, Richert L, Schramm C, Wahib R, Bunders MJ, Altfeld M. Tissue-resident NK cells differ in their expression profile of the nutrient transporters Glut1, CD98 and CD71. PLoS One. 2018 Jul 20;13(7):e0201170. doi: 10.1371/journal.pone.0201170. eCollection 2018.</citation>
    <PMID>30028872</PMID>
  </reference>
  <results_reference>
    <citation>Dunsmore G, Koleva P, Ghobakhloo N, Sutton R, Ambrosio L, Meng X, Hotte N, Nguyen V, Madsen KL, Dieleman LA, Huang V, Elahi S. Lower Abundance and Impaired Function of CD71+ Erythroid Cells in Inflammatory Bowel Disease Patients During Pregnancy. J Crohns Colitis. 2019 Feb 1;13(2):230-244. doi: 10.1093/ecco-jcc/jjy147.</citation>
    <PMID>30272151</PMID>
  </results_reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 18, 2018</study_first_submitted>
  <study_first_submitted_qc>October 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2018</study_first_posted>
  <last_update_submitted>October 24, 2018</last_update_submitted>
  <last_update_submitted_qc>October 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Marwa Aboelim Shafeik</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>immunophenotyping by flow cytometry of cd71</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

